On March 18, 2025, reports indicated that drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars. This comes amid fears that top-selling medicines, including Merck's cancer immunotherapy Keytruda, could face tariffs.
The pharmaceutical industry has argued that tariffs on the EU would increase drug costs and create access barriers for patients, potentially endangering priorities outlined in President Donald Trump's health-related executive orders. Merck declined to comment on the situation.
This macroeconomic risk could lead to higher operating costs and pricing pressures for Merck, impacting the profitability of its globally manufactured products. The company is actively investing in U.S. manufacturing to mitigate potential future pharmaceutical tariffs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.